Pharmacotherapy of urinary incontinence in the elderly

Der Internist
K F Becher

Abstract

The prevalence and the incidence of Urinary Incontinence is growing. Women suffer predominantly from stress and mixed urinary incontinence and men from urge incontinence. In elderly people, the pathophysiological and the physiological change in the lower urinary tract system must be considered as well as an underlying multimorbidity. Stress urinary incontinence is among others caused by an insufficient urethral closure mechanism and urge incontinence is followed by unhibited detrusor contractions. Medical treatment is beside other important conservative options only one part of the treatment strategy in incontinence. Duloxetine, a serotonine-norepinephrine reuptake inhibitore can increase activity of the external urethral sphincter and is able to reduce incontinence episodes in up to 64 %. Antagonists of muscarinic receptors can reduce urgency, frequency and urge incontinence as well as increase bladder capacity significantly. In Germany, darifenacin, fesoterodin, oxybutynin, propiverine, solifenacin, tolterodine and trospium chloride are available to treat urge incontinence. The efficacy of these agents are almost comparable in the elderly with the exception of oxybutynin IR. However, tolerability is different and not well stu...Continue Reading

References

Aug 3, 2001·American Journal of Obstetrics and Gynecology·M A HarveyG A Wells
Feb 22, 2002·Neurourology and Urodynamics·Paul AbramsUNKNOWN Standardisation Sub-committee of the International Continence Society
Jul 13, 2002·American Journal of Obstetrics and Gynecology·Peggy A NortonUNKNOWN Duloxetine Urinary Incontinence Study Group
Aug 16, 2002·European Urology·Mark GoepelMartin C Michel
Sep 23, 2003·The Journal of Urology·Roger R DmochowskiUNKNOWN Duloxetine Urinary Incontinence Study Group
Feb 14, 2004·BJOG : an International Journal of Obstetrics and Gynaecology·Philip van KerrebroeckUNKNOWN Duloxetine Urinary Incontinence Study Group
Apr 12, 2005·The Journal of Urology·Gamal M GhoniemUNKNOWN Duloxetine/Pelvic Floor Muscle Training Clinical Trial Group
Feb 21, 2007·Der Urologe. Ausg. A·A Welz-Barth
Nov 24, 2007·Der Urologe. Ausg. A·C SeifK-P Jünemann
Mar 28, 2008·The Annals of Pharmacotherapy·Matthew A CantrellBenton Stamper
Jun 24, 2008·Journal of Cataract and Refractive Surgery·David F ChangUNKNOWN ASCRS Cataract Clinical Committee
Dec 17, 2008·Current Opinion in Ophthalmology·Salwa Abdel-Aziz, Nick Mamalis
Dec 4, 2009·Indian Journal of Urology : IJU : Journal of the Urological Society of India·Madhu S AgrawalRicha Jaiman
Oct 15, 2010·Journal of the American Geriatrics Society·David StaskinMichael G Oefelein
Mar 23, 2011·Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology·R Patel-GadhiaP Patil
Feb 16, 2012·Clinical Interventions in Aging·Anne G VinsnesArnfinn Seim
Sep 19, 2012·European Urology·Malcolm G LucasUNKNOWN European Association of Urology
Dec 12, 2012·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Hasan Ali TufanCabir Alan
Apr 17, 2013·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Gary D NovackNancy E Martin
Apr 27, 2013·Zeitschrift für Gerontologie und Geriatrie·K BecherM Wehling
Jul 15, 2015·Der Urologe. Ausg. A·I SoljanikR Kirschner-Hermanns
Nov 1, 2015·Der Anaesthesist·T PiephoUNKNOWN German Society of Anesthesiology and Intensive Care Medicine

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.